Related Experiment Video
Updated: Jul 8, 2026

LipidUNet-Machine Learning-Based Method of Characterization and Quantification of Lipid Deposits Using iPSC-Derived Retinal Pigment Epithelium
Published on: July 28, 2023
[New possibilities in the pharmacologic prevention of age-related macular degeneration]
Insights
Treating endothelial dysfunction may prevent or slow vision loss from age-related macular degeneration (AMD). Medications like ACE-inhibitors, AR-blockers, statins, aspirin, and trimetazidine are suggested for AMD patients and those at risk.
Area of Science:
- Ophthalmology and Cardiovascular Medicine
- Endothelial Dysfunction Research
- Pharmacological Interventions
Context:
- The vascular system's physiological and pathological uniformity suggests shared therapeutic strategies.
- Endothelial dysfunction is a key factor in cardiovascular diseases and increasingly implicated in age-related macular degeneration (AMD).
- Current AMD etiology and therapy remain largely unknown, highlighting the need for novel treatment approaches.
Purpose:
- To propose treating endothelial dysfunction as a therapeutic strategy for age-related macular degeneration (AMD).
- To investigate the potential benefits of cardiovascular medications in managing AMD.
- To identify patient groups who could benefit from preventative or therapeutic interventions targeting endothelial dysfunction in AMD.
Summary:
- Endothelial dysfunction contributes to AMD pathogenesis.
- ACE-inhibitors, AR-blockers, statins, and aspirin possess pleiotropic effects beneficial for endothelial health.
- Trimetazidine may serve as an adjuvant therapy to restore retinal tissue metabolism.
- These medications can help rebalance vasodilators/vasoconstrictors, growth factors, inflammatory mediators, and prothrombotic/fibrinolytic factors.
Impact:
- Suggests a novel, preventative, and therapeutic approach for AMD by targeting endothelial dysfunction.
- Recommends specific pharmacological treatments (ACE-inhibitors, AR-blockers, statins, aspirin, trimetazidine) for different AMD patient groups.
- Emphasizes the importance of managing cardiovascular risk factors to mitigate AMD progression.
Abstract:
The beneficial effect achieved by the treatment of endothelial dysfunction in chronic cardiovascular diseases is already an evidence belonging to the basic treatment of the disease. Given the fact that the vascular system is uniform and consubstantial both physiologically, pathophysiologically and in terms of therapy, and that it plays a key role in age-related macular degeneration (AMD)--a disease leading to tragic loss of vision with its etiology and therapy being unknown--endothelial dysfunction should be treated. The pleiotropic effects of ACE-inhibitors, AR-blockers and statins help to restitute the balance between vasodilators and vasoconstrictors in endothelial dysfunction caused by oxidative stress, the balance of growth factors and their inhibitors, pro- and anti-inflammatory substances and prothrombotic and fibrinolytic factors, inhibit the formation of oxidative stress and its harmful effects; while aspirin with its pleiotropic effects acting as an antiaggregation substance on platelets helps to set the endothelial layer back to its normal balance regarding its vasodilating, antithrombotic, antiadhesive and anti-inflammatory functions; trimetazidine as an adjuvant agent helps to normalize, to restore the disturbed metabolism of the retinal tissue functioning insufficiently, in the end. For the above reasons it is suggested that, as a part of long term primary and/or secondary prevention, the following groups of patients with AMD receive--taking into consideration all possible side effects--ACE-inhibitor and/or AR blocker and statin and aspirin treatment, and trimetazidine as adjuvant medicine 1. those without maculopathy but being above the age of 50 and having risk factors inducing endothelial dysfunction; 2. those, who already developed AMD in one eye as a prevention in the second, unaffected eye; and 3. those patients who developed AMD in both eyes in order to ameliorate or merely slow the progression of the disease. Besides, it is advisory to eliminate AMD risk factors inducing oxidative stress with consecutive endothelial dysfunction.
More Related Videos
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
10:14Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Diabetic Retinopathy
Pharmacodynamics in Geriatric Patients: Effects of Age
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
iPS Cell Differentiation
Angle Closure Glaucoma: Treatment